Ardent Health, Inc. (ARDT) Form 8-K — Aug 4, 2026
Ardent Health reported second quarter 2026 revenue of $1.62 billion, down 1.4% year over year, with net income attributable to the company falling to $17 million ($0.12 per diluted share) from $73 million ($0.52) a year ago. Adjusted EBITDA declined 32.3% to $115 million, pressured by lower surgeries and admissions and by the prior-year quarter having captured two quarters of New Mexico state directed payment benefits. Cash generation was the bright spot: operating cash flow rose 67% year over year to $197 million, and Ardent ended the quarter with $724 million of cash, $992 million of available liquidity, and a 0.8x net leverage ratio.
Key figures
- Eps
- 0.12
- Revenue
- 1622245000
- Guidance
- Reaffirmed FY2026 revenue of $6,400-$6,700 million and Adjusted EBITDA of $485-$535 million; net income guidance lowered to $110-$163 million (from $129-$183 million) and diluted EPS to $0.78-$1.15 (from $0.90-$1.27).
- Net Income
- 16899000
- Total Debt
- $1.1 billion
- Revenue Yoy
- -1.4%
- Cash Position
- 724476000
- Admissions Yoy
- -1.0%
- Adjusted Ebitda
- 114951000
- Adjusted Ebitdar
- 156530000
- Six Month Revenue
- 3224115000
- Net Leverage Ratio
- 0.8x
- Adjusted Ebitda Yoy
- -32.3%
- Operating Cash Flow
- 197000000
- Total Surgeries Yoy
- -2.9%
- Available Liquidity
- 992000000
- Q2 Share Repurchases
- 1.4 million shares for $13 million
- Six Month Revenue Yoy
- +2.6%
- Prior Year Diluted Eps
- 0.52
- Operating Cash Flow Yoy
- +67%
- Adjusted Admissions Yoy
- +2.5%
- Inpatient Surgeries Yoy
- -7.5%
- Impact Savings Target2026
- $70 million, raised from $55 million previously
- Lease Adjusted Net Leverage Ratio
- 2.6x
- Remaining Repurchase Authorization
- 34000000
- Net Patient Service Revenue Per Adjusted Admission
- $17,864, down 3.9% Y/Y
Price after filing
Close on the filing date to close N calendar days later (from $10.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.